Update on antithrombin I (fibrin).

Antithrombin I (fibrin) is an important inhibitor of thrombin generation that functions by sequestering thrombin in the forming fibrin clot, and also by reducing the catalytic activity of fibrinbound thrombin. Thrombin binding to fibrin takes place at two classes of non-substrate sites: 1) in the fibrin E domain (two per molecule) through interaction with thrombin exosite 1; 2) at a single site on each gamma' chain through interaction with thrombin exosite 2. The latter reaction results in allosteric changes that down-regulate thrombin catalytic activity. Antithrombin I deficiency (afibrinogenemia), defective thrombin binding to fibrin (antithrombin I defect) found in certain dysfibrinogenemias (e.g. fibrinogen Naples 1), or a reduced plasma gamma' chain content (reduced antithrombin I activity), predispose to intravascular thrombosis.
AuthorsMichael W Mosesson
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 98 Issue 1 Pg. 105-8 (Jul 2007) ISSN: 0340-6245 [Print] Germany
PMID17597999 (Publication Type: Journal Article, Review)
Chemical References
  • Fibrinogens, Abnormal
  • Fibrin
  • Thrombin
  • Binding Sites
  • Fibrin (deficiency, metabolism, physiology)
  • Fibrinogens, Abnormal
  • Humans
  • Thrombin (metabolism)
  • Thrombosis (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: